25 Drugs Added to Knowledgebase

We recently added 25 new drugs to the knowledgebase:
 

• Domvanalimab a monoclonal antibody for TIGIT for the treatment of non-small cell lung cancer (NSCLC), unresectable or metastatic gastric, esophageal and gastro-esophageal junction adenocarcinomas is being developed by Arcus Biosciences
• RGI-2001 an alpha-galactosylceramide analog for prophylaxis of acute graft-versus-host disease (aGVHD) is being developed by REGiMMUNE
• mRNA-4157/V940 a cancer vaccine for the treatment of Stage III/IV melanoma following complete resection is being developed by Moderna and Merck
• Glofitamab a bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is being developed by Roche
• Elranatamab a bispecific antibody for the treatment of relapsed or refractory multiple myeloma is being developed by Pfizer
• Odronextamab a bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is being developed by Regeneron Pharmaceuticals
• PRA023 an anti-TL1A monoclonal antibody for the treatment of ulcerative colitis, Crohn’s disease and sclerosis-associated interstitial lung disease is being developed by Prometheus Biosciences
• NCX 470 a nitric oxide (NO)-donating prostaglandin analogue for the treatment of open-angle glaucoma or ocular hypertension is being developed by Nicox
• TAK-279 a TYK2 inhibitor for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis is being developed by Takeda, Nimbus Therapeutics
• Talquetamab a bispecific antibody for the treatment of relapsed or refractory multiple myeloma is being developed by Johnson & Johnson
• Lyme disease vaccine - Valneva a vaccine for the prevention of Lyme disease is being developed by Pfizer and Valneva
• Stannous protoporphyrin, iron sucrose a heme oxygenase inhibitor to reduce the risk of postoperative complications following cardiothoracic surgery is being developed by Renibus Therapeutics
• Ganaplacide an imidazolopiperazine for the treatment of malaria is being developed by Novartis
• ARV-471 a proteolysis targeting chimeric (PROTAC) for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. is being developed by Arvinas
• Glutamic acid decarboxylase-65 (GAD65) a glutamic acid decarboxylase for the preservation of endogenous insulin production is being developed by Diamyd Medical
• IONIS-FB-LRx an antisense drug for the treatment of immunoglobulin A nephropathy (IgAN) and Age-Related Macular Degeneration (AMD) is being developed by Roche and Ionis Pharmaceuticals
• Denileukin diftitox a fusion protein for the treatment of persistent or recurrent cutaneous T-cell lymphoma is being developed by Citius Pharmaceuticals
• Lutetium-177-edotreotide an octreotide-derived somatostatin analog attached to a low-energy beta-emitting therapeutic radioisotope for the treatment of gastroenteropancreatic neuroendocrine tumors is being developed by ITM Isotope Technologies Munich SE
• Acoziborole a benzoxaborole for the treatment of Human African trypanosomiasis caused by Trypanosoma brucei gambiense is being developed by Sanofi
• Baxdrostat an aldosterone synthase inhibitor for the treatment of treatment-resistant hypertension and primary aldosteronism is being developed by CinCor Pharma
• Zolbetuximab an anti-CLDN18.2 monoclonal antibody for the treatment of Claudin 18.2 (CLDN18.2)-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma is being developed by Astellas Pharma
• Ecopipam a dopamine D1 receptor antagonist for the treatment of Tourette syndrome is being developed by Emalex Biosciences and Psyadon Pharmaceuticals
• Anacaulase a proteolytic enzyme for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns is being developed by MediWound
• RVT-3101 a Tumor necrosis factor α-like ligand 1A (TL1A) antibody for the treatment of ulcerative colitis and Crohn’s Disease is being developed by Roivant Sciences
• TAK-755 an ADAMTS13 replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) is being developed by Takeda

 
The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 1,111 pipeline and recently approved drugs supported by 2,934 announced and published study results